Baldo B A, Pham N H
Molecular Immunology Laboratory, Kolling Institute of Medical Research, Royal North Shore Hospital of Sydney, St. Leonards, NSW, Australia.
Chem Res Toxicol. 1994 Nov-Dec;7(6):703-21. doi: 10.1021/tx00042a001.
As a result of recent research and development, an expanding range of in vitro assays for the detection of drug-reactive IgE antibodies is now available for the diagnosis of individual drug allergies. Continuing immunochemical studies on drugs implicated in allergic reactions via further development of specific immunoassays and production of drug-protein conjugates will allow us to build up a picture of the repertoire of drug and drug-derived B-cell allergenic determinant structures and to identify and predict cross-reactivities. Although we have made good progress in identifying some drug B-cell determinants, we remain ignorant of drug T-cell determinants and, indeed, of the nature of T-cell recognition of all nonpeptide molecules. Demonstration that drugs specifically recognize T-cells from drug-allergic patients may reveal associations with HLA phenotypes, the nature and location of interaction between drug and MHC molecules, and the nature and identity of drug or drug-derived T-cell antigens. A knowledge of the molecular nature of T-cell determinants inducing allergic responses is fundamental to therapeutic attempts to modulate these deleterious reactions. The possibility now exists for the allergenic screening of drugs as part of their toxicological evaluation, and identification of allergenic structures on drugs also has implications for the testing of allergenic activity and sensitizing potential of other chemicals in our environment. Obvious and important areas for the application of our methods and findings are the pharmaceutical and cosmetic industries.
由于近期的研究与开发,现在有越来越多的体外检测方法可用于检测药物反应性IgE抗体,以诊断个体药物过敏。通过进一步开发特异性免疫测定法和生产药物 - 蛋白质缀合物,对与过敏反应相关的药物进行持续的免疫化学研究,将使我们能够构建药物和药物衍生的B细胞过敏原决定簇结构的图谱,并识别和预测交叉反应性。尽管我们在识别一些药物B细胞决定簇方面取得了良好进展,但我们对药物T细胞决定簇以及所有非肽分子的T细胞识别性质仍然一无所知。证明药物特异性识别药物过敏患者的T细胞,可能会揭示与HLA表型的关联、药物与MHC分子之间相互作用的性质和位置,以及药物或药物衍生的T细胞抗原的性质和身份。了解诱导过敏反应的T细胞决定簇的分子性质是调节这些有害反应的治疗尝试的基础。现在有可能在药物毒理学评估中对药物进行过敏原筛选,并且识别药物上的过敏原结构也对测试我们环境中其他化学物质的过敏活性和致敏潜力有影响。我们的方法和研究结果应用的明显且重要的领域是制药和化妆品行业。